Is a complete RCKT research report available?

No complete published report is available for Rocket Pharmaceuticals, Inc. (RCKT) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Rocket Pharmaceuticals, Inc. (RCKT)

NASDAQ: RCKT · USD

$3.21

+0.07 (+2.2%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first RCKT analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	350.5M
Net income (ttm)	-209.4M
EPS (ttm)	-$1.88
Shares out	109.2M
Volume	1,126,430
Beta	0.45
Price target	$9.39	+192.5%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -209.4M
EPS (ttm): -$1.88
Market cap: 350.5M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All RCKT indicators

Market & fundamental data

Available fields

191

Groups with data

Currency

USD

Showing 191 of 191 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001281895
Company name	Rocket Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	77313F106
Employees	202
Employees Change	-97%
Employees Change Percent	-32.44
Enterprise value	$230.9M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US77313F1066
Last refreshed	2026-07-31
Market cap	$350.5M
Market cap category	Small-Cap
Price	$3.21
Price currency	USD
Sector	Healthcare
Sector PE	45.51
Sector PE Fwd	24.23
Sic	2834
Symbol	RCKT
Website	https://www.rocketpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-59.74%
EV Sales Forward	11.19x
FCF yield	-51.29%
P/B ratio	1.47x
PS Forward	16.98x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-209.4M
Net Income Growth Quarters	5%
Net Income Growth Years	1%
Profit Per Employee	$-1M
ROA	-35.14
Roa5y	-27.79
ROCE	-82.73
ROE	-64.41
Roe5y	-49.34
ROIC	-37.96

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	6.65%
Cagr3y	-43.74%
Cagr5y	-39.01%
EPS Growth Quarters	5
EPS Growth Years	3
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$285.4M
Cash	$144.4M
Current Assets	$149.8M
Current Liabilities	$24.5M
Debt	$24.8M
Debt Equity	$0.1
Equity	$238M
Interest Coverage	-114.1
Liabilities	$47.4M
Long Term Assets	$135.6M
Long Term Liabilities	$22.9M
Net Cash	$119.6M
Net Cash By Market Cap	$34.13
Net Cash Growth	-59.15%
Net Debt Equity	$-0.5
Tangible Book Value	$173.7M
Tangible Book Value Per Share	$1.59
WACC	6.66

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.12
Net Working Capital	$-16.1M
Quick ratio	5.9
Working Capital	$125.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-12.83%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	6.65%
200-day SMA	3.58
3Y total return	-82.2%
50-day SMA	3.25
50-day SMA vs 200-day SMA	50under200
5Y total return	-91.56%
All Time High	67.48
All Time High Change	-95.24%
All Time High Date	2021-02-08
All Time Low	2.19
All Time Low Change	46.58%
All Time Low Date	2025-05-27
ATR	0.2
Beta	0.45
Beta1y	2.04
Beta2y	1.74
Ch YTD	-8.55
High	3.21
High52	5.45
High52 Date	2026-03-10
High52ch	-41.1%
Low	3.11
Low52	2.53
Low52 Date	2026-06-11
Low52ch	26.88%
Ma50ch	-1.26%
Premarket Change Percent	0
Premarket Price	$3.14
Premarket Volume	1,156
Price vs 200-day SMA	-10.39%
RSI	42.34
RSI Monthly	33.87
RSI Weekly	46.19
Sharpe ratio	0.4x
Sortino ratio	0.75
Total Return	-12.83%
Tr YTD	-8.55
Tr1m	-4.75%
Tr1w	-2.13%
Tr3m	-7.76%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	13
Analyst Count Top	9
Analyst Price Target Top	$10.6
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$0.34
Earnings Revenue Estimate	13,336,360x
Operating Income	$-212.6M
Price target	$9.39
Price Target Change	$193
Price Target Change Top	$230

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	86,935,300%
Float Percent	79.62%
Net Borrowing	-1,000
Shares Insiders	3.63%
Shares Institutions	73.44%
Shares Out	109,193,549
Shares Qo Q	0.31%
Shares Yo Y	12.83%
Short Float	19.06%
Short Ratio	5.46
Short Shares	15.18

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-215M
Adjusted OCF	-214,839,000
Average Volume	1,806,696.85x
Bv Per Share	2.18
CAPEX	$-169,000
Ch1m	-4.75
Ch1w	-2.13
Ch1y	6.65
Ch3m	-7.76
Ch3y	-82.2
Ch5y	-91.56
Ch6m	-9.58
Change	2.23%
Change From Open	2.23
Close	3.14
Days Gap	0
Depreciation Amortization	10,182,000
Dollar Volume	3,615,840.3
Earnings Date	2026-08-05
Earnings Time	amc
EBIT	$-215.9M
EBITDA	$-205.7M
EPS	$-1.88
F Score	1
FCF	$-179.8M
FCF EV Yield	-77.86x
FCF Per Share	$-1.65
Financing CF	147,000
Fiscal Year End	December
Founded	1,999
Goodwill	39,154,000
Investing CF	179,250,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	3.63
Ma150ch	-11.55%
Ma20	3.57
Ma20ch	-10.13%
Net CF	-221,000
Next Earnings Date	2026-08-10
Open	3.14
Optionable	Yes
Position In Range	100
Post Close	3.21
Postmarket Change Percent	-0.93
Postmarket Price	$3.18
Ppne	69,453,000
Pre Close	3.14
Price Date	2026-07-30
Ptbv Ratio	2.02
Relative Volume	0.62x
Share Based Comp	35,221,000
Tr6m	-9.58%
Us State	New Jersey
Volume	1,126,430

Rocket Pharmaceuticals, Inc. (RCKT)

Coverage state: Market snapshot only — no published research

Generate the first RCKT analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · RCKT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All RCKT indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on RCKT

Frequently asked questions